PT-141 is a lab-made peptide — a short chain of amino acids, the building blocks of proteins. Its formal name is bremelanotide, and unlike erection pills that work on blood flow, PT-141 works in the brain: it switches on receptors tied to sexual *desire* rather than the mechanics1. It is also one of the few research-adjacent peptides that crossed the finish line — the FDA approved it as Vyleesi in 2019 for a specific type of low sexual desire in some premenopausal women5.
In plain terms: a brain-acting "desire" peptide that, for one narrow use, is an actual approved medicine — not a gray-market research chemical.
What it is
PT-141 is a cyclic heptapeptide — "hepta" means seven amino acids, and "cyclic" means the chain is looped into a ring rather than left as a straight strand. That ring shape makes it more stable and helps it hold its structure long enough to act1.
Its recipe is copied from a natural hormone your body already makes: alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH is the master signal of the melanocortin system — the same family of signals that controls skin pigment, appetite, and, as it turns out, sexual arousal. PT-141 is a trimmed, stabilized cousin of that hormone4.
How it works: the melanocortin receptors
Melanocortin signals act through a set of receptors named MC1R through MC5R. Think of them as five different "locks," each opening a different door:
- MC1R sits on pigment cells in the skin (the tanning door).
- MC3R and MC4R sit mostly in the brain (the appetite-and-arousal doors).
PT-141 is a melanocortin receptor agonist — "agonist" just means a key that turns a lock *on*. It acts mainly at MC4R (and MC3R), the brain receptors1. Activating MC4R in specific brain regions is thought to nudge the dopamine pathways that drive sexual desire and arousal4.
In plain terms: it turns a brain "desire" switch, one step *before* the blood-flow machinery that Viagra-type drugs act on. That is the whole reason it was studied for low desire rather than erectile mechanics.
Pharmacokinetics: how long it lasts
PT-141 is given as an injection under the skin. Its half-life — the time for the blood level to drop by half — is about 2.7 hours according to the FDA label5.
Here is the interesting quirk: its *effects* on sexual function seem to outlast its *blood level*. Early human work reported the first erectile response within roughly 30–60 minutes of dosing, with the effect persisting for hours beyond what a 2.7-hour half-life would suggest2. That gap — short in the blood, longer in effect — shows up with several brain-acting peptides, because what matters is how long the *receptor signal* echoes, not how long the molecule lingers.
| Property | Detail |
|---|---|
| Class | Synthetic cyclic 7-amino-acid peptide (analogue of alpha-MSH) |
| Main targets | Melanocortin receptors, chiefly MC4R and MC3R (brain) |
| Route (approved product) | Subcutaneous injection, on-demand before sexual activity5 |
| Plasma half-life | About 2.7 hours5 |
| Onset in early trials | First response about 30–60 minutes2 |
| Regulatory status | FDA-approved as Vyleesi (2019) for HSDD in premenopausal women5 |
What the studies actually found
PT-141's evidence base is unusually strong for a peptide in this space, because it went through real controlled human trials. Here is how the picture built, oldest to newest:
| Study | Model | Key result | Year |
|---|---|---|---|
| Molinoff et al.1 | Review + early human | First described PT-141 as a brain-acting melanocortin agonist producing dose-dependent erectile responses in men | 2003 |
| Diamond et al.2 | Human (men, ED) | Intranasal PT-141 produced measurable erectile responses versus placebo; first response about 30 minutes | 2004 |
| Kingsberg et al. — RECONNECT3 | Human (women, HSDD; two phase-3 trials) | More women on PT-141 showed improved desire and reduced distress than on placebo; nausea most common side effect | 2019 |
| FDA approval5 | Regulatory | Bremelanotide approved as Vyleesi for acquired, generalized HSDD in premenopausal women | 2019 |
| Dhillon & Keam — drug profile4 | Review | Summarized the approval, mechanism, and on-demand subcutaneous profile | 2019 |
The two phase-3 trials — known together as the RECONNECT studies — are the centerpiece3. They enrolled premenopausal women with HSDD (hypoactive sexual desire disorder): persistent, distressing low sexual desire. Across both trials, a meaningfully larger share of women on PT-141 reported improved desire and less distress than on placebo. Honest framing: the benefit was real but modest, and it was measured on desire questionnaires, not a dramatic single number.
Practical notes and handling
The approved product, Vyleesi, is an on-demand subcutaneous injection taken before anticipated sexual activity rather than a daily medicine5. Because PT-141 can cause transient small rises in blood pressure, the label states it was not studied in — and is not intended for — people with uncontrolled high blood pressure or known cardiovascular disease5. This page describes the approved product's studied profile; it is not instructions.
Honest limitations and safety
- Narrow approved use. The approval is specifically for premenopausal women with acquired, generalized HSDD — not a general libido booster, and not approved for men despite the early male trials2.
- Nausea is common. It was the most frequent side effect in the phase-3 trials, and some participants used an anti-nausea medicine3.
- Blood pressure and pigment effects. Transient blood-pressure rises are noted on the label, and because it touches the melanocortin system, focal skin/gum darkening has been reported with melanocortin agonists generally5.
- "PT-141" is not always Vyleesi. A regulated approval for one product does not make every peptide sold under the "PT-141" name regulated, pure, or equivalent. This page takes no position on sourcing.
Latest research
- Long-term and label data. The NIH LiverTox monograph and the FDA label together remain the standard reference points for bremelanotide's approved profile and safety monitoring, and are the best-verified sources to check as the record updates65.
- Melanocortin system, broadly. The same receptor family PT-141 targets is an active research area for appetite and metabolic conditions, which keeps interest in MC4R pharmacology alive well beyond sexual health4.
We keep this section current as new trials and label updates land.
The short version
PT-141 (bremelanotide) is a stabilized copy of the hormone alpha-MSH that acts on brain melanocortin receptors — the desire side of sexual function, not the plumbing. For one narrow use, low sexual desire in some premenopausal women, it is an FDA-approved medicine (Vyleesi) backed by two phase-3 trials showing a real but modest benefit. It clears the blood in a few hours, nausea is its most common downside, and "approved for one thing" is not the same as "proven for everything." For contrast, see its non-selective cousin Melanotan II, and the broader research peptides overview.